Abstract: Compound of formula (I): wherein: n represents 0 or 1, R1 represents hydrogen, arylalkyl, alkyl, acyl, alkoxycarbonyl, arylalkoxycarbonyl or trifluoroacetyl, R2 represents alkyl, X represents oxygen, chlorine, OR3, SR4 or NOR5, R3 represents hydrogen, alkyl, acyl, alkoxycarbonyl or arylalkoxycarbonyl, R4 represents hydrogen, alkyl or aryl, R5 represents hydrogen or optionally substituted alkyl, represents a single or double bond, Ar represents aryl or heteroaryl, its isomers and addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful as facilitators of memory and cognition and antalgic agents.

Abstract: The present invention relates to a new solid controlled-release pharmaceutical composition obtained by thermoforming, in the hot state, a mixture based on polymers belonging to the polymethacrylate family and medicinal active ingredient(s).

Abstract: Process for the industrial synthesis of isoindoline by catalytic hydrogenation of phthalonitrile, and its application in the synthesis of 2-(S)-benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)-butyric acid, its pharmaceutically acceptable salts and its hydrates.

Abstract: The invention concerns a coal tar extract with reduced polycyclic aromatic hydrocarbon and benzo(a)pyrene content and a method for obtaining same using two sequentially linked distillation systems. The invention also concerns cosmetic and dermatological preparations containing said resulting coal tar extract.

Abstract: The invention relates to compounds of formula (I): A—G1—Cy—G2—Cy—G3—B  (I) wherein: A represents NR1C(Q)R2, C(Q)NR2R3 or NR1C(Q)NR2R3, B represents NR1C(Q)R2, C(Q)NR2R3, NR1C(Q)NR2R3, C(Q)OR1, NR1C(Q)OR2 or NR2R3, G1 and G3 represent an optionally substituted alkylene chain, Cy represents a ring structure and G2 represents a chain and medicinal products containing the same which are useful in treating or in preventing melatoninergic disorders.

Abstract: The invention relates to compounds of formula (I): wherein: R1, R2 and R3 are as defined in the description, X is as defined in the description, Y represents an oxygen atom, a sulphur atom, a C(H)q group, SO or SO2, n is equal to from 0 to 5, A represents a NR5R6 group, and medicinal products containing the same which are useful in treating or in preventing melatoninergic disorders.

Abstract: The invention relates to compound of formula (I): A—G1—Cy—G2—Cy′—G3—B  (I) wherein: A represents a grouping NR1C(Q)R2, C(Q)NR2R3 or NR1C(Q)NR2R3, B represents a grouping NR1C(Q)R2, NR1C(Q)NR2R3, C(Q)NR2R3, C(Q)OR1, NR1C(Q)OR2 or NR2R3, G1 and G3 represent an optionally substituted alkylene chain, Cy and Cy′, which are different, represent a ring structure or G2 represents a chain and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.

Abstract: The invention relates to compound of the general formula (I): R—O—A  (I) wherein: R represents the radical of formula (II): A is as defined in the description, and medicinal products containing the same which are useful in treating or in preventing cancer.

Abstract: A compound selected from those of formula (I): wherein: X represents oxygen, sulphur, or NR3 wherein R3 is as defined in the description, Y represents oxygen, sulphur, NR3, or may represent single bond in certain cases, T represents nitrogen, carbon, or CH, A represents single bond, alkylene, arylene, cycloalkylene, heterocycloalkylene, heteroarylene, or —SO2—R4— wherein R4 is as defined in the description, W represents hydroxy, alkoxy, aryloxy, arylalkoxy, cycloalkyloxy, heterocycloalkyloxy or heteroaryloxy, or hydroxyamino, U1 represents hetero, or alkylene wherein one or more of carbon may optionally be replaced by one or more hetero atoms, V1 represents arylene, heteroarylene,or heterocycloalkylene, U2 represents single bond, hetero or alkylene wherein one or more carbon may optionally be replaced by one or more hetero atoms, V2 represents aryl, heteroaryl, or heterocycloalkyl, Ra, Rb, Rc, which may be identical or different, each independently of the others r

Abstract: The invention concerns novel 3-oxo-(2H)-1,2,4-triazine derivatives of general formula (I) in which R1 represents: hydrogen, when A is an optionally substituted nitrogen atom; a linear or branched 1-C4 alkyl group; a C1-C4phenyl alkyl group, the phenyl ring being optionally substituted by one or several groups such as C1-C4 alkyl, C1-C3 alkoxy, halogen, trifluoromethyl. R2 represents: hydrogen; a linear or branched C1-C4 alkyl radical; a C1-C4 phenyl or phenylalkyl group, the phenyl ring being optionally substituted by one or several groups such as C1-C4 alkyl, C1-C3 alkoxy, halogen, trifluoromethyl. A represents an oxygen atom or a nitrogen atom optionally NR3 substituted. R3 represents hydrogen or a methyl group.

Abstract: A compound of formula (I) in which: m, and n, which may be identical or different, represent 0 or 1, X and Y, which may be identical or different, represent hydrogen or halogen or alkyl, trihaloalkyl, alkoxy, hydroxyl, cyano, nitro, amino, alkylamino, or dialkylamino, Z represent a linear or branched C4 to C12 alkylene chain in which one or more —CH2— are optionally replaced by any one of the following atoms or groups: —NR—, —O—, —S—, —SO—, SO2—, or —CONH—, or by a substituted or unsubstituted heterocylcic, A forms, with two adjacent carbon atoms of the phenyl ring, a phenyl, naphthyl or tetrahydronaphthyl ring or a heterocycle, represents any one of the groups as defined in the description, its optical isomers and its addition salts with a pharamaceutically and acceptable acid or base, and medicinal products containing the same which are useful as anticancer agents.

Abstract: Compound of formula (I): in which: n is 1 or 2, X represents alkylene, alkenylene, alkynylene or optionally substituted arylene or heteroarylene, R10 represents hydrogen or alkyl and R11 and R12 together form a bond, or alternatively R12 represents hydrogen or alkyl and R10 and R11 together form a bond, R2, R3 and R4 each independently of the others represents hydrogen, alkyl, hydroxyalkyl, alkoxy, alkoxycarbonyl, aryl, arylalkyl or aryloxyalkyl, or two of R2, R3 and R4 form a cycloalkyl radical. Medicinal products containing the same are useful in the treatment of cardiovascular diseases.

Abstract: Compound of formula (I): wherein: n represents 2 or 3, R1 represents optionally substituted alkyl, cycloalkyl or optionally substituted phenyl, R2 represents amino, optionally substituted amidino, optionally substituted guanidino or optionally substituted isothioureido, Ar represents aryl or heteroaryl, X1 represents hydroxy or optionally substituted amino, isomers thereof, and also salts thereof with a pharmaceutically acceptable acid or base, and which medicinal products containing the same/are useful as trypsin-related serine protease inhibitors.

Abstract: A compound selected from those of formula (I): in which: X and Y represent hydrogen, halogen, hydroxy, mercapto, cyano, nitro, alkyl, alkoxy, trihaloalkyl, optionally substituted amino, methylenedioxy, or ethylenedioxy, R1 represents hydrogen, or alkyl, R2 represents hydrogen, hydroxy, alkyl, alkoxy, alkylcarbonyloxy, or optionally substituted ammo, R3 and R4 represent hydrogen, or alkyl, A represents —CH═CH—, or —CH(R5)—CH(R6)— wherein R5 and R6 are as defined in the description, their isomers, N-oxides, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of cancer.

Abstract: Compound of formula (I): wherein: R represents: a group of formula (i):  wherein X, Y and W are as defined in the description, or a group of formula (ii): —A—G  (ii) wherein: A represents a single bond or an optionally substituted alkylene chain, G represents a group selected from hydrogen, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —OR2, —O—T1—NR3R4, —O—T1—NR2—T′1—NR3R4, —NR3R4, —NR2—T1—NR3R4, —NR2—T1—OR5, —NR2—T1—CO2R6, —NR2—T1—C(O)R6, —C(O)—NR3R4, —C(O)—NR2—T2, —O—C(O)T2, —O—C(S)—T2, —NR2—C(O)—T2, —NR2—C(S)—T2, —O—C(O)—O—T2, —O—C(O)—NR2—T2, —O—C(S)—O—T2, —O—C(S)—NR2—T2, —NR2—C(O)—O—T2,

Abstract: A compound selected from those of formula (I): wherein: R1 represents hydrogen, optionally substituted alkyl, cycloalkyl or heterocycloalkyl or a group of formula (G): wherein A1 represents single, —CH2—, —CH2—CH2— or —N(CH3)— or oxygen or sulphur, and X1 and X2, which may be identical or different, each represent carbon or nitrogen, R represents hydrogen or linear or branched (C1-C6)alkyl,  represents a saturated ring having from 4 to 7 ring members, n represents integer wherein 1≦n≦6, Ar represents aryl or heteroaryl, its isomers, N-oxydes and pharmaceutically-acceptable acid or base addition salts thereof.

Abstract: The invention concerns novel indole piperazine derivatives of Formula (I): It also concerns a method for preparing said compounds and their use as therapeutically active substances, in particular for treating or preventing diseases related to the dysfunction of 5 -HT1-like receptors.

Abstract: Compounds of formula (I): R—NH—A—CO—NH—NH—(W)n—Z   (I) wherein: n is 0 or 1, W represents —CO— or S(O)r wherein r is 0, 1 or 2, Z represents a group selected from aryl, arylalkyl, heteroaryl and heteroarylalkyl, each optionally substituted, R represents a grouping selected from: Z1—T—CO—, Z1—O—T—CO—, Z1—T—O—CO—, Z1—T—S(O)q— wherein Z1, T and q are as defined in the description, A represents alkylene, alkenylene or alkynylene each having from 3 to 8 carbon atoms, alkylenecycloalkylene, cycloalkylenealkylene, alkylenecycloalkylenealkylene, alkylenearylene, arylenealkylene, alkylenearylenealkylene a grouping wherein B1 is as defined in the description, or A forms with the adjacent nitrogen atom a grouping as defined in the description. Medicinal products containing the same are useful as Neuropeptide Y receptors ligands.

Abstract: Sample displacement chromatography is performed at low operating pressures (less than 30 bar) and/or at high sample loading (in excess of 500 mg/cm2 column area), with product recovery being effected in a non-gradient manner. The low operating pressures permit the use of simple and inexpensive apparatus. Non-gradient product recovery allows the desired product to be allowed in solutions with advantageously high concentration. Materials which may be purified include pharmaceuticals, pharmaceutical excipients, fine chemicals, biochemicals, X-ray contrast agents, chelating agents, peptides, proteins, oligonucleotides and vaccines. Apparatus embodiments include sample displacement chromatography apparatus comprising one or more ion exchange columns in direct combination with one or more desalting columns, and multicolumn chromatography apparatus permitting switching between a series separation mode and a parallel extraction mode.

Abstract: Compound of formula (I): wherein: n is 0 or 1, W represents —CO— or S(O)q and q is 0, 1 or 2, G represents a G1, G2, G3 or G4 group as defined in the description, Z represents alkyl, aryl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted.